Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Opioid Analgesic Labeling Guidance Will Highlight Drug Abuse Potential

Executive Summary

FDA is developing a guidance on labeling for opioid analgesics, designed to highlight the abuse risk of the drugs.

You may also be interested in...



Long-Term Opioid Efficacy Studies Will Take Years, Gottlieb Says

Trials will be mandated as part of new authority granted by SUPPORT Act and are intended to determine whether opioid efficacy decreases with long-term use.

Ligand Avinza Once-Daily Dosing Will Be Core Promo Message For Elan Opioid

Ligand will focus on Avinza once-daily dosing as the opioid's primary marketing message following the March 20 approval of the extended-release morphine drug licensed from Elan

Ligand Avinza Once-Daily Dosing Will Be Core Promo Message For Elan Opioid

Ligand will focus on Avinza once-daily dosing as the opioid's primary marketing message following the March 20 approval of the extended-release morphine drug licensed from Elan
UsernamePublicRestriction

Register

PS038247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel